These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21506251)

  • 21. Hepatocellular carcinoma and liver transplantation.
    Washburn K; Halff G
    Curr Opin Organ Transplant; 2011 Jun; 16(3):297-300. PubMed ID: 21505342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do preoperative inflammatory markers impact on outcome after liver transplantation for hepatocellular carcinoma?
    Sapisochin G; Yao FY; Roberts JP
    Ann Surg; 2011 Aug; 254(2):383; author reply 383-4. PubMed ID: 21694577
    [No Abstract]   [Full Text] [Related]  

  • 23. Selection criteria for patients with hepatocellular carcinoma in liver transplantation.
    Kaido T; Takada Y; Uemoto S
    Transplantation; 2009 Aug; 88(3):442-3; author reply 443. PubMed ID: 19667951
    [No Abstract]   [Full Text] [Related]  

  • 24. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience.
    Mazzaferro V; Bhoori S; Sposito C; Bongini M; Langer M; Miceli R; Mariani L
    Liver Transpl; 2011 Oct; 17 Suppl 2():S44-57. PubMed ID: 21695773
    [No Abstract]   [Full Text] [Related]  

  • 25. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression.
    Vivarelli M; Cucchetti A; Piscaglia F; La Barba G; Bolondi L; Cavallari A; Pinna AD
    Liver Transpl; 2005 May; 11(5):497-503. PubMed ID: 15838913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B virus DNA and hepatocellular carcinoma recurrence after resection: the lower, the better!
    You H; Jia JD
    J Gastroenterol Hepatol; 2010 Dec; 25(12):1812-4. PubMed ID: 21091989
    [No Abstract]   [Full Text] [Related]  

  • 27. Is tumor biopsy necessary?
    Müllhaupt B; Durand F; Roskams T; Dutkowski P; Heim M
    Liver Transpl; 2011 Oct; 17 Suppl 2():S14-25. PubMed ID: 21744470
    [No Abstract]   [Full Text] [Related]  

  • 28. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
    Toso C; Meeberg GA; Bigam DL; Oberholzer J; Shapiro AM; Gutfreund K; Ma MM; Mason AL; Wong WW; Bain VG; Kneteman NM
    Transplantation; 2007 May; 83(9):1162-8. PubMed ID: 17496530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Strategy to improve the prognosis of liver transplantation for hepatocellular carcinoma].
    Fan J; Xu Y
    Zhonghua Wai Ke Za Zhi; 2008 Nov; 46(21):1602-5. PubMed ID: 19094749
    [No Abstract]   [Full Text] [Related]  

  • 30. Markers for microvascular invasion in hepatocellular carcinoma: where do we stand?
    Gouw AS; Balabaud C; Kusano H; Todo S; Ichida T; Kojiro M
    Liver Transpl; 2011 Oct; 17 Suppl 2():S72-80. PubMed ID: 21714066
    [No Abstract]   [Full Text] [Related]  

  • 31. Is there a customised immunosuppressive regimen for patients transplanted with hepatocellular carcinoma?
    Majno P; Giostra E; Mentha G;
    J Hepatol; 2005 Oct; 43(4):577-84. PubMed ID: 16118027
    [No Abstract]   [Full Text] [Related]  

  • 32. [Surgical treatment for hepatocellular carcinoma].
    Chen XP
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):411-2. PubMed ID: 19645135
    [No Abstract]   [Full Text] [Related]  

  • 33. Is the treatment of hepatocellular carcinoma on the waiting list necessary?
    Majno P; Lencioni R; Mornex F; Girard N; Poon RT; Cherqui D
    Liver Transpl; 2011 Oct; 17 Suppl 2():S98-108. PubMed ID: 21954097
    [No Abstract]   [Full Text] [Related]  

  • 34. [Liver transplantation for hepatocellular carcinoma and potential application of PSI].
    Decaens T; Duvoux C
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S257-62. PubMed ID: 20004332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver transplantation for hepatocellular carcinoma.
    Durand F; Belghiti J
    Hepatogastroenterology; 2002; 49(43):47-52. PubMed ID: 11941982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.
    Vivarelli M; Dazzi A; Zanello M; Cucchetti A; Cescon M; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Transplantation; 2010 Jan; 89(2):227-31. PubMed ID: 20098287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural killer cells play divergent roles in shaping the outcome of hepatitis C virus recurrence following liver transplantation.
    Golden-Mason L
    Liver Transpl; 2009 Apr; 15(4):357-9. PubMed ID: 19326413
    [No Abstract]   [Full Text] [Related]  

  • 38. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma.
    Reddy MS; Manas DM
    Transplantation; 2007 Feb; 83(3):367-8. PubMed ID: 17297420
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index.
    Kao WY; Chiou YY; Hung HH; Chou YH; Su CW; Wu JC; Huo TI; Huang YH; Lin HC; Lee SD
    Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):528-36. PubMed ID: 21537128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatocellular carcinoma: a pledge for evidence-based medicine.
    Braillon A; Nguyen-Khac E
    Am J Med; 2008 Oct; 121(10):e7; author reply e11-2. PubMed ID: 18823845
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.